Repeated treatment with mirtazapine induces brain-derived neurotrophic factor gene expression in rats

Journal of Physiology and Pharmacology

Volumn 56, Issue 4, 2005, Pages 661-671

  Rogoz Z ^a   Skuza, G ^a   Legutko, B ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 HT2A syndrome; Imipramine; Mirtazapine; mRNA BDNF; Rats; Repeated treatment

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; IMIPRAMINE; MESSENGER RNA; MIRTAZAPINE; SEROTONIN 2A AGONIST; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE; DRUG DERIVATIVE; MIANSERIN; SEROTONIN AGONIST; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; GENE EXPRESSION; HEAD TWITCH; HIPPOCAMPUS; MALE; NONHUMAN; NORTHERN BLOTTING; RAT; ANIMAL; ANIMAL BEHAVIOR; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECT; GENETICS; METABOLISM; TIME; WISTAR RAT;

AMPHETAMINES; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; IMIPRAMINE; MALE; MIANSERIN; RATS; RATS, WISTAR; RNA, MESSENGER; SEROTONIN AGONISTS; TIME FACTORS;

EID: 31144440641     PISSN: 08675910     EISSN: 08675910     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Davis R, Wilder MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996; 5: 389-402.
2. De Boer T, Maur G, Raitieri M, De Vos CJ, Wieringa J, Pinder RM. Neurochemical and autonomic profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988; 27: 399-408.
3. 2 selective adrenoreceptor antagonist Org 3770 (Mirtazapine, Remeron) enhances noradrenergic and serotonergic neurotransmission. Hum Psychopharmacol 1995; 10: S107-S108.
4. De Boer T, Nefkens F, Van Helvoirt A, Van Delft AML. Differences in modulation of noradrenergic and serotonergic transmission by the alpha 2 adrenoceptor antagonist, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996; 277: 852-860.
5. Holm K, Markham A. Mirtazapine. A review of its use in major depression. Drugs 1999; 57: 607-631.
6. Nickolson VJ, Wieringa JH, Van Delft AML. Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naunyn-Schmied Arch Pharmacol 1992; 319: 48-53.
7. McGrath C, Burrows GD, Norman TR. Neurochemical effects of the enantiomers of mirtazapine in normal rats. Eur J Pharmacol 1998; 356: 121-126.
8. 1-adrenergic receptors J Physiol Pharmacol 2002; 53: 105-116.
9. 3 receptors. Pol J Pharmacol 2002; 54: 381-389.
10. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997; 12 (suppl 3): S7-S14.
11. Skolnik P. Antidepressants for the new millennium. Eur J Pharmacol 1999; 375: 31-40.
12. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000; 405: 365-373.
13. Vetulani J, Nalepa I. Antidepressants: past, present, and future. Eur J Pharmacol 2000; 405: 351-363.
14. 3 receptors in rats. J Physiol Pharmacol 2003; 54: 257-270.
15. Rogóż Z, Budziszewska B, Kubera M, Basta-Kaim A, Jaworska-Feil L, Skuza G, Lasoń W. Effects of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol 2005; 56: 49-61.
16. Smith MA, Makino S, Kvetnansky R, Post MN. Stress alters the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995; 15: 1768-1777.
17. Duman RS. Depression: a case of neuronal life and death. Biol Psychiatry 2004; 56: 140-145.
18. Chen B, Dowlatshahi D, MacQueen GM, Wong J-F, Young LT. Increased hippocampal BDNF immunoreactivity in subject treated with antidepressant medication. Biol Psychiatry 2001; 50; 260-265.
19. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in depressed patients. Psychiatry Res 2002; 109: 143-148.
20. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M. Alternations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54: 70-75.
21. Aydemmir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuro-Psychopharmacol Biol Psychiatry 2005; 29: 261-265.
22. Gervasoni N, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G, Karege F. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005; 51: 234-238.
23. Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S. Effect of treatment on serum brain-derived neurotrophic factor level in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005; (in press).
24. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997; 56: 131-137.
25. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produced antidepressant effects in behavioural models of depression. J Neurosci 2002; 22: 3251-3261.
26. Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037: 204-208.
27. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T, Meuth S, Nagy A, Greene RW, Nestler E. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004; 102: 10827-10832.
28. Ivy AS, Rodriguez FG, Garcia C, Chen MJ, Russo-Neustadt AA. Noradrenergic and serotonergic blockade inhibits BDNF mRNA activation following exercise and antidepressant. Pharmacol Biochem Behav 2003; 75: 81-88.
29. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-7547.
30. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of camp response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-2372.
31. Coppell AL, Pei Q, Zetterstrom TSC. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 2003; 44: 903-910.
32. Dias BG, Banerjee SB, Duman RS, Vajdya VA. Differential regulation of brain-derived neurotrophic factor transcripts by antidepressant treatments in the adult rats brain. Neuropharmacology 2003; 45: 553-563.
33. De Foubert G, Carney SL, Robinson CS. Destexhe EJ, Tomlinson R, Hicks CA, Murray TK, Gaillard JP, Deville C, Xhenseval V, Thomas CE, O'Neill MJ, Zetterstrom TSC: Fluoxetine-induced changein rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 2004; 128: 597-604.
34. Russo-Neustadt AA, Alejandre H, Garcia C, Ivy AS, Chen MJ. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology 2004; 29: 2189-2199.
35. Jacobsen JPR, Mork A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 2004; 1024: 183-192.
36. Legutko B, Li X, Skolnik P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 2001; 40: 1019-1027.
37. Nowak G, Legutko B, Szewczyk B, Papp M, Sanak M, Pilc A. Zinc treatment induces cortical brain-derived neurotrophic factor gene expresion. Eur J Pharmacol 2004; 492: 57-59.
38. Maj J, Bijak M, Dziedzicka-Wasylewska M, Rogóż Z, Skuza G, Tokarski K. The effect of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology 1996; 127: 73-82.
39. Maj J, Moryl E. Effect of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm [Gen Sect] 1992; 88: 143-156.
40. Maj J, Moryl E. Effect of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists. Eur Neuropsychopharmacol 1993; 3: 85-94.
41. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA. cAMP response element-binding protein is essential for the up-regulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002; 22: 3262-3268.
42. Russo-Neustadt A, Beard RC, Cotman CW, Exercise, antidepressant medications, and enhanced brain-derived neurotrophic factor expression. Neuropsychopharmacology 1999; 21: 679-682.
43. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. Effect of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003; 54: 703-709.
44. Mateo Y, Fernandes-Pastor B, Meana JJ. Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoreceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br J Pharmacol 2001; 133: 1362-1370.
45. Yoshitake T, Reenila I, Ogreen SO, Hokfelt T, Kehr J. Galanin attenuates basal and antidepressant drug-induced increase of extra-cellular serotonin and noradrenaline levels in the rat hippocampus. Neurosci Lett 2003; 339: 239-242.
46. Hutter P, Johansson M, Saria A, Humpel C. Acute and chronic noradrenergic regulation of neurotrophic messenger RNA expression in rat hippocampus: evidence from lesions and organotypic cultures. Neurosciences 1996; 70: 15-29.
47. Heninger GR, Charney DS. Mechanisms of action of antidepressant treatments: Implications for the etiology and treatment of depressive disorders. In Psychppharmacology: the third generation of progress (Meltzer HY, ed) 1987: 535-544: New York: Raven.